NSE与非小细胞肺癌化疗预后的关系  

Prospective value of NSE in non small-cell lung cancer patients with chemotherapy

作　　者：曹亮[1] 郭彦伟[1] 王志伟[1] 刘超[1] 刘艳[1] 潘静[1] 

机构地区：[1]郑州人民医院颐和医院肿瘤科,河南郑州450000

出　　处：《中国现代医生》2014年第17期32-34,38,共4页China Modern Doctor

摘　　要：目的探讨肿瘤标记物NSE与非小细胞肺癌患者化疗效果的相关性。方法回顾性分析我院62例非小细胞肺癌患者,48例(77.4%)患者接受2个周期培美曲赛联合顺铂治疗方案,14例(22.6%)接受易瑞沙靶向治疗的方案。治疗前后比较NSE水平的变化以及按照RECIST标准比较肿瘤大小。结果 2周期化疗后,在肿瘤缩小或稳定的患者中NSE水平较治疗前降低56%。NSE水平下降≥16%,总反应率80%,18.1%病例稳定,1.9%进展。然而,NSE下降<16%,总反应率6.1%,60.6%稳定,33.3%进展。NSE下降≥16%患者无进展生存期(19.12±2.31)个月长于NSE下降<16%的(8.56±1.49)个月(P<0.001)。NSE下降水平与患者总生存率无关(P>0.05)。结论 NSE是非小细胞肺癌患者预后的一个敏感的特异性指标,同时是一个可以预测非小细胞肺癌患者化疗及靶向治疗疗效的指标。NSE下降超过16%的非小细胞肺癌患者无进展生存期更长。Objective To evaluating the prognoses of tumor marker NSE （neuron-specific enolase） regarding to chemotherapy response in non smallcell lung cancer （NSCLC） patients. Methods Sixty-two with locally advanced NSCLC patients were included in this study. All these patients were given 2 courses of pemetrexed plus cisplatin chemotherapy （77.4%） or tyrosine kinase inhibitor （22.6%）. The treatment response was determined by the changes of NSE serum level and RECIST criteria before and after 2 courses chemotherapy. Results After two cycles of chemotherapy treatments, the patients who reached an objective response showed a reduction of NSE levels of 56% compared to its basal level. For a NSE reduction achieved ≥16% showed an overall response in 80% of cases, stable disease in 18.1% and progression in 1.9 %, while patients that did not achieve a reduction i〉 16% had an overall response of 6.1%, stable disease of 60.6 % and progression of 33.3 %. PFS was longer in patients with a i〉 16% reduction in NSE （19.12±2.31 vs 8.56±1.49 months ,P 〈 0.001 ）. Reduction of NSE was not a predictive factor of OS. Conclusion NSE is a sensitive and specific tumor marker of NSCLC ,and A NSE level reduction is also a sensitive prognosis factor of chemotherapy and TKI therapy in NSCLC patients. A≥ 16% reduction in NSE levels is associated with a longer PFS.

关 键 词：非小细胞肺癌 化疗 靶向治疗 NSE 预后 

分 类 号：R734.2[医药卫生—肿瘤]